- Home
- MIST vs FATE Comparison
MIST vs FATE Comparison
Compare MIST & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | FATE |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 125.6M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MIST | FATE |
|---|---|---|
| Price | $1.04 | $2.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.00 | $4.10 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.93 |
| 52 Week High | $3.06 | $3.23 |
Technical Indicators
Market Signals| Indicator | MIST | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 39.37 |
| Support Level | $1.01 | $2.25 |
| Resistance Level | $1.42 | $2.88 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 7.41 | 0.17 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.